To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia

Phase 2CompletedNCT04500132

Enzychem Lifesciences Corporation63 enrolled

Overview

Prevention of COVID-19 infection to severe pneumonea or ARDS

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

COVID-19

Interventions

EC-18DRUG

EC-18 QD

Placebo EC-18DRUG

Placebo EC-18 QD

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * Male or female age 19 years or older * Pathologically confirmed diagnosis of COVID-19 Infection to Pneumonia Exclusion Criteria: * Pathologically confirmed diagnosis of bacterial pneumonia or viral pneumonia * Pregnant or nursing at the time of signing informed consent * Known sensitivity to any study medication * Unwilling or unable to complete study diary * Any other condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the protocol

Locations (1)

Chungbuk National University Hospital

Cheongju-si, South Korea

Outcomes

Primary Outcomes

Rate of transition to ARDS

Time frame: 14 days after starting IP administration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.